Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Big bio/pharma would rather 'make than buy,' says PharmSourceLeader in contract bio/pharma industry intelligence predicts ongoing in-house manufacture
By: PharmSource A premier leader in market intelligence for the global contract bio/pharma industry, PharmSource details its analysis in a just-issued trend report, Bio/Pharma CapEx Trends: Sponsor Spending on In-House Capacity Trounces Outsourcing. Jim Miller, the founder and president of PharmSource, is the report’s lead author. He said that based on detailed research and analysis of the financial investments bio/pharma companies are making in their captive manufacturing capacity, it’s clear that companies would rather “make than buy.” “Capital expenditure trends are an indicator of the industry’s propensity to outsource its manufacturing requirements,” In developing the report, PharmSource’ This PharmSource report complements its 2012 trend report, Are CMOs Losing the Make-versus- PharmSource is the recognized authority of unbiased knowledge about the global bio/pharmaceutical contract services industry. The company’s proprietary publications, databases, research tools and analyses inform buyers and sellers of bio/pharma contract services about industry trends, activities and partnership opportunities. Since 1996, CMOs, CDMOs and CROs worldwide have looked to PharmSource for critical information delivered with timeliness and integrity. Learn more online. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|